Skip to main content
Equibles
VERA logo

VERA · Vera Therapeutics, Inc. · Metrics

Track VERA — free

Use VERA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VERA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$30.06 +1.14 (+3.94%)
Russell 2000 member Rebalance outlook locked
Market Cap
$2.13B
Shares
72.06M
Volume · Oct 20 1.19M Avg daily vol (3M) 2.15M

VERA metrics

67 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$30.06
Market cap
$2.13B

Price action

20 metrics
Price change (1W)
+4.3%
Price change (30D)
-15.6%
Price change (3M)
-21.8%
Price change (6M)
-30.5%
Price change (YTD)
-42.9%
Price change (1Y)
-7.4%
Trailing year
Price change (5Y)
+70.9%
52-week high
$55.67
52-week low
$24.10
Change from 52-week high
-48.1%
Change from 52-week low
+20.0%
Annualized volatility
61.5%
Annualized volatility (3M)
58.8%
Beta
1.3
RSI (14D)
42.7
Price vs SMA 50
-10.2%
Price vs SMA 200
-23.4%
Avg volume (3M)
2.15M
Relative volume
0.6
Average dollar volume
$69.92M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
72.06M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
5.0
reciprocal yield 20.2%
FCF yield
-16.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-19.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-05

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$415.76M
Net income (TTM)
−$401.89M
Trailing 12 months
Diluted EPS (TTM)
$-5.86
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-6.07
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-5.86
Operating cash flow per diluted share (TTM)
$-4.92
Free cash flow per diluted share (TTM)
$-4.93
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$3.83
Stock compensation per diluted share (TTM)
$0.73
Book value per share
—

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+12.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-98.6%
Return on assets
-75.4%
Debt / equity
0.2
Current ratio
10.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$338.91M
Quick ratio
10.9
Interest coverage
-55.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$423.93M
Latest balance sheet
Cash & equivalents
$48.88M
Total assets
$532.98M
Total debt
$75.23M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$338.65M
Capital expenditures (TTM)
$258,000
R&D (TTM)
$261.87M
SG&A (TTM)
—
Stock compensation (TTM)
$49.78M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
222
13F filer change QoQ
-9
Institutional ownership
108.8%
Conviction holders (share of 13F filers)
3.7%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+2.5%
Holder tenure
10.9
Price vs estimated holder cost
+37.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
16.1%

Short interest

3 metrics
Short interest
23.9%
Latest settlement · 7.8 days to cover
Days to cover
7.8d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.33M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1831828 CUSIP 92337R101 13F (30d) 11 filings 11 filers Visit website Investor relations